Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo): Patient Characteristics and Predictors of Long-term Survival
Overview
- Phase
- Not Applicable
- Intervention
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Sponsor
- Bayer
- Enrollment
- 1180
- Locations
- 1
- Primary Endpoint
- Overall survival from initiation of Ra-223
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
In this observational study researchers want to gather more information about the characteristics of patients treated with Radium-223 (Xofigo) who had survived over a long period of time prostate cancer that had spread to other places in the body and keeps growing even when the amount of testosterone in the body is reduced to very low levels (metastatic castration-resistant prostate cancer, mCRPC). In addition researchers want to identify the factors which may contribute to survival over a long period of time in those patients. Radium-223 (Ra-223) is an alpha particle-emitting radioactive agent approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
Radium-223 dichloride (Xofigo, BAY88-8223)
Patients with mCRPC who received treatment of Ra-223.
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Outcomes
Primary Outcomes
Overall survival from initiation of Ra-223
Time Frame: Retrospective analysis from Jan 2013 to Dec 2019
Secondary Outcomes
- Percentage of Prostate Specific Antigen (PSA) (unit: µg/L) response after Ra-223(Retrospective analysis from Jan 2013 to Dec 2019)